Journal article icon

Journal article

Farnesyltransferase inhibitors.

Abstract:

The targeting of molecular abnormalities in neoplasms may provide an opportunity to improve the selectivity of cancer therapy. Ras mutations are a common genetic event in human cancers. Other genetic changes in tumors can signal through ras-dependent pathways as well. The targeting of ras through the inhibition of Ras protein farnesylation is one new cancer treatment strategy under clinical evaluation. Several farnesyltransferase inhibitors (FTIs) have been evaluated in phase I trials. The to...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Bernhard, E More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Journal:
Seminars in oncology
Volume:
28
Issue:
5 Suppl 16
Pages:
86-93
Publication date:
2001-10-05
DOI:
EISSN:
1532-8708
ISSN:
0093-7754
URN:
uuid:d4045498-f675-4007-8695-8757a28d936f
Source identifiers:
118185
Local pid:
pubs:118185

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP